Personal information

No personal information available

Activities

Collapse all

Works (4)

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis

Neurology
2024-12-24 | Journal article
DOI: 10.1212/WNL.0000000000210049
Contributors: Hans-Peter Hartung; Ralph H.B. Benedict; Thomas Berger; Robert A. Bermel; Bruno Brochet; William M. Carroll; Mark S. Freedman; Trygve Holmøy; Rana Karabudak; Carlos Nos et al.
Source: check_circle
Crossref

Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies

Neurology Neuroimmunology & Neuroinflammation
2024-11 | Journal article
DOI: 10.1212/NXI.0000000000200328
Contributors: Wei Z. Yeh; Anneke Van Der Walt; Olga G. Skibina; Tomas Kalincik; Raed Alroughani; Allan G. Kermode; Marzena J. Fabis-Pedrini; William M. Carroll; Jeannette Lechner-Scott; Cavit Boz et al.
Source: check_circle
Crossref

Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome

Brain
2024-04-04 | Journal article
DOI: 10.1093/brain/awad409
Contributors: Helmut Butzkueven; Anne-Louise Ponsonby; Mark S Stein; Robyn M Lucas; Deborah Mason; Simon Broadley; Trevor Kilpatrick; Jeannette Lechner-Scott; Michael Barnett; William Carroll et al.
Source: check_circle
Crossref

Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal

Multiple Sclerosis Journal
2022-01 | Journal article
DOI: 10.1177/13524585211059766
Contributors: Alan J Thompson; William Carroll; Olga Ciccarelli; Giancarlo Comi; Anne Cross; Alexis Donnelly; Anthony Feinstein; Robert J Fox; Anne Helme; Reinhard Hohlfeld et al.
Source: check_circle
Crossref
How many people are using ORCID?